Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Author Correction: Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
Luszczak S, Simpson BS, Stopka-Farooqui U, Sathyadevan VK, Echeverria LMC, Kumar C, Costa H, Haider A, Freeman A, Jameson C, Ratynska M, Ben-Salha I, Sridhar A, Shaw G, Kelly JD, Pye H, Gately KA, Whitaker HC, Heavey S. Luszczak S, et al. Among authors: gately ka. Sci Rep. 2020 Nov 11;10(1):19870. doi: 10.1038/s41598-020-76679-x. Sci Rep. 2020. PMID: 33177621 Free PMC article.
Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM, Madden SF, Gaynor N, AlSultan D, Le Gal M, Eustace AJ, Gately KA, Hughes C, Davies AM, Mahgoub T, Ballot J, Toomey S, O'Connor DP, Gallagher WM, Holmes FA, Espina V, Liotta L, Hennessy BT, O'Byrne KJ, Hasmann M, Bossenmaier B, O'Donovan N, Crown J. Collins DM, et al. Among authors: gately ka. Clin Cancer Res. 2021 Feb 1;27(3):807-818. doi: 10.1158/1078-0432.CCR-20-2007. Epub 2020 Oct 29. Clin Cancer Res. 2021. PMID: 33122343 Free PMC article. Clinical Trial.
Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer.
Luszczak S, Simpson BS, Stopka-Farooqui U, Sathyadevan VK, Echeverria LMC, Kumar C, Costa H, Haider A, Freeman A, Jameson C, Ratynska M, Ben-Salha I, Sridhar A, Shaw G, Kelly JD, Pye H, Gately KA, Whitaker HC, Heavey S. Luszczak S, et al. Among authors: gately ka. Sci Rep. 2020 Sep 1;10(1):14380. doi: 10.1038/s41598-020-71263-9. Sci Rep. 2020. PMID: 32873828 Free PMC article.
PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer.
Luszczak S, Kumar C, Sathyadevan VK, Simpson BS, Gately KA, Whitaker HC, Heavey S. Luszczak S, et al. Among authors: gately ka. Signal Transduct Target Ther. 2020 Jan 31;5(1):7. doi: 10.1038/s41392-020-0109-y. Signal Transduct Target Ther. 2020. PMID: 32296034 Free PMC article. Review.
Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC.
Ryan SL, Beard S, Barr MP, Umezawa K, Heavey S, Godwin P, Gray SG, Cormican D, Finn SP, Gately KA, Davies AM, Thompson EW, Richard DJ, O'Byrne KJ, Adams MN, Baird AM. Ryan SL, et al. Among authors: gately ka. Lung Cancer. 2019 Sep;135:217-227. doi: 10.1016/j.lungcan.2019.07.006. Epub 2019 Jul 12. Lung Cancer. 2019. PMID: 31446998